[ad_1]
The developer of Russia’s Sputnik V coronavirus vaccine said Friday it had signed a partnership with an India-based drugmaker for the production of 200 million doses of the two-dose jab.Â
The Russian Direct Investment Fund (RDIF), which backed the development of Sputnik V, said in a statement it had partnered with Stelis Biopharma “to produce and supply a minimum of 200 million doses of the Russian Sputnik V vaccine.â€
Stelis Biopharma is expected to be able to start supplying the vaccine from the second half of the year.Â
RDIF, added that Stelis – the biopharma unit of global pharmaceutical company Strides – will work with the Russian wealth fund to provide supplies “beyond the initial agreement.â€Â
RDIF head Kirill Dmitriev said that the “significant vaccine volumes†produced with Stelis “will help widen access to the vaccine on a global scale.â€Â
[ad_2]
Source link